Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal as a 78-year-old can be” but fears what happens now he has to stop taking it. Peter Almond finished a trial for Donanemab in September having been on the drug for three years.